Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiri Minarik

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Blood Cancer Journal|September 26, 2023
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal GammopathiesViera Sandecka, Tereza Popkova, Martin Stork, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
The New England Journal of Medicine|June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaThierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
The Lancet. Haematology|March 1, 2023
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyAnnie Cowan, Federico Ferrari, Samuel S Freeman, et al.
Blood Cancer Discovery|June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple MyelomaMaximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Blood Cancer Journal|September 26, 2023
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal GammopathiesViera Sandecka, Tereza Popkova, Martin Stork, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
BMC Cancer|January 16, 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceJiri Minarik, Tomas Pika, Jakub Radocha, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
The New England Journal of Medicine|June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaThierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
The Lancet. Haematology|March 1, 2023
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyAnnie Cowan, Federico Ferrari, Samuel S Freeman, et al.
Blood Cancer Discovery|June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple MyelomaMaximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Pageof 6